Skip to main content
. 2017 Aug 4;313(4):H839–H853. doi: 10.1152/ajpheart.00702.2016

Fig. 7.

Fig. 7.

The nitric oxide synthase inhibitor N-nitro-l-arginine methyl ester (l-NAME) blocks afobazole-induced changes in lymphatic pumping. A: representative trace of a lymphatic vessel first treated for 10 min each with 50, 100, and 150 µM afobazole followed by a washout period for reestablishment of contractions similar to baseline and then treated with vehicle (water) and 50, 100, and 150 µM afobazole. B: representative trace of a lymphatic vessel first treated for 10 min each with 50, 100, and 150 µM afobazole followed by a washout period for reestablishment of contractions similar to baseline and then treated with l-NAME and 50, 100, and 150 µM afobazole. C–H: summarized data (means ± SE) from 5 isolated lymphatic vessels in the water-treated group and 7 isolated lymphatic vessels in the l-NAME-treated group. Each vessel was from a different rat. Data represent average values of each parameter obtained during the last 2 min of baseline and water or l-NAME periods and a 2-min period during each afobazole concentration staring 4 min after the administration of afobazole. C: contraction frequency (CF) did not significantly change in either group (two-way ANOVA, P = 0.1470). D: end-diastolic diameter (EDD) normalized to maximal passive diameter (MaxD) was significantly elevated in l-NAME-treated lymphatics after treatment with 100 and 150 µM afobazole. E: end-systolic diameter (ESD) normalized to MaxD (ESD/MaxD) was significantly elevated in the water- but not l-NAME-treated group after 100 and 150 µM afobazole. F: amplitude of contraction (AMP) normalized to MaxD (AMP/MaxD) was significantly reduced in the water-treated group after 100 and 150 µM afobazole but only after 150 µM afobazole in the l-NAME-treated group. G: ejection fraction (EF) was significantly reduced in the water-treated group after treatment with 100 and 150 µM afobazole but not in the l-NAME-treated group. H: fractional pump flow (FPF) was significantly reduced in the water- but not l-NAME-treated group after 150 µM afobazole. Data were analyzed by repeated-measures two-way ANOVA with the Geisser-Greenhouse correction; when this test identified a significant trend, multiple comparisons were performed using Dunnett’s test.